Clinical trial
Insulin Glulisine in Healthy Lean and Obese Subjects
NCT00311077 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00311077 |
|---|---|
| Title | Insulin Glulisine in Healthy Lean and Obese Subjects |
| Official title | Pharmacodynamic and Pharmacokinetic Properties of Insulin Glulisine (Apidra) in Comparison to Insulin Lispro (Humalog) in Healthy Lean and Obese Subjects |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | Insulin Glulisine |
| Start date | Apr 1, 2004 |
| Primary completion | Oct 1, 2004 |
| First posted | Apr 5, 2006 |
| Last update posted | Dec 7, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: